Gallery

…return on investment in pharma R&D is already below the cost of capital, and projected to hit zero within just 2 or 3 years. And this despite all efforts by the industry to fix R&D and reverse the trend.

The billion-dollar pharma startup that Silicon Valley has totally missed

Link

The billion-dollar pharma startup that Silicon Valley has totally missed

How Valeant had a bright idea but took it too far

Link

How Valeant had a bright idea but took it too far